In light of serious problems identified in the NIH Clinical Center Pharmaceutical Development Section last year, NIH launched a multifaceted effort to ensure that processes for patient safety and quality of care at the hospital are of the highest standards.  Accordingly, NIH hired two companies specializing in quality assurance for manufacturing and compounding — Working Buildings and Clinical IQ — to evaluate all of its facilities producing sterile or infused products for administration to research participants.  This evaluation is underway and preliminary findings have identified facilities not in compliance with quality and safety standards, and not suitable for the production of sterile or infused products.  As a result, production has been suspended in two facilities: a National Cancer Institute laboratory engaged in cell therapy production and a National Institute of Mental Health facility producing positron emission tomography (PET) materials.

Related posts:

  1. Statement on the new crib safety standards On June 28th, new mandatory safety standards for infant cribs will take effect, helping to ensure a safe sleep environment for infants in the United States. The new standards released by the Consumer Product Safety Commission (CPSC) require manufacturers and retailers to meet new safer crib standards, which include stopping the manufacture and sale of […]...
  2. Medicare Card, NIH suspends operations in its Pharmaceutical Development Section Medicare Card, NIH suspends operations in its Pharmaceutical Development Section...
  3. Dialysis Facility Compare links consumers with detailed information about the 4,700 dialysis facilities certified by Medicare Dialysis Facility Compare links consumers with detailed information about the 4,700 dialysis facilities certified by Medicare...
  4. Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease...
  5. Medicare Card, Global pandemic of fake medicines poses urgent risk, scientists say Medicare Card, Global pandemic of fake medicines poses urgent risk, scientists say...
  6. Press Statement on the NSABB Review of H5N1 Research The U.S. government remains concerned about the threat of influenza, for the risks it poses seasonally, as well as its potential to cause a pandemic....
  7. Medicare Card, Preliminary results show improvement in MS symptoms Medicare Card, Preliminary results show improvement in MS symptoms...
  8. NIH and FDA announce awards to advance regulatory science The National Institutes of Health will award $9.4 million over three years to support four research projects in regulatory science. This research is conducted in partnership with the U.S. Food and Drug Administration, which will contribute approximately $950,000. These projects will better inform scientists and regulatory reviewers alike about medical product safety, and improve the […]...
  9. Medicare Card, Learning About Genetically Modified Foods “Genetically modified,” and “genetically engineered.” These are the terms often heard when referring to certain foods. What do they mean for you as a consumer? According to the U.S. Food and Drug Administration, foods that have been genetically modified, like fruits, vegetables, oils, cereals, etc., were introduced to the market in the 1990s.  Since then, […]...
  10. Medicare Card, NIH names new clinical sites in Undiagnosed Diseases Network Medicare Card, NIH names new clinical sites in Undiagnosed Diseases Network...
  11. Medicare Card, NIH funds studies to improve type 2 and prediabetes treatment Medicare Card, NIH funds studies to improve type 2 and prediabetes treatment...
  12. Medicare Card, Give Green Gifts with Energy Star Products Medicare Card,Give Green Gifts with Energy Star Products...
  13. Medicare Card, NIH scientists map first steps in flu antibody development Medicare Card, NIH scientists map first steps in flu antibody development...
  14. Medicare Card, Gene therapy staves off blindness from retinitis pigmentosa in canine model Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for […]...
  15. Medicare Card, Seven genetic risk factors found to be associated with common eye disorder Medicare Card, Seven genetic risk factors found to be associated with common eye disorder...